# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Personalis (NASDAQ:PSNL) with a Buy and maintains $8.5 pri...
Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, announced new data from an AstraZeneca ph...
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Personalis (NASDAQ:PSNL) with a Buy and lowers the price ta...